Daily Newsletter

31 October 2023

Daily Newsletter

31 October 2023

Anitoa introduces multi-bay modular qPCR instrument

Maverick qPCR instruments integrate technological advancements developed by Anitoa Systems.

RanjithKumar Dharma October 31 2023

Anitoa Systems has expanded its Maverick line of qPCR products with the launch of the 96-well multi-bay modular real-time PCR (qPCR) instrument.

The Maverick MQx96 is the company’s first larger-format qPCR instrument, which comes with several independently operable modules.

The MQx96 and MQx48 instruments are offered in two well formats, including 96-well (6 x 16) and 48-well (3 x 16).

Each instrument comprises either six or three 16-well qPCR modules, which can be independently controlled using a unified software interface.

MQx96 is ideal for labs that require a continuous process for running small batches of samples.

Maverick qPCR instruments incorporate technological advancements developed by Anitoa Systems.

They include a low-light complementary metal-oxide-semiconductor (CMOS) four-channel fluorescence optics system, enabling rapid and multiplexed DNA detection.

The MQ96 and MQ48 are modular systems, featuring individual reaction chambers that can be independently heated and cooled.

As a result, they can achieve reaction times 30%–40% faster than conventional large-block qPCR systems.

Anitoa Systems CEO Dr Zhimin Ding said: “We are excited to offer laboratories worldwide a modular solution for rapid and pipelined nucleic acid tests to help combat diseases by detecting pathogens in humans, as well as our food and environment.

“We believe our multi-bay modular qPCR instruments and the integrated software offer features that meet the needs of labs seeking higher throughput testing while being extremely flexible.”

Is the healthcare industry ready to fully embrace the benefits of digitalization and AI?

The healthcare, pharma, and medical devices industries are often risk-averse compared to other sectors when adopting new technologies. However, mainly due to COVID-19, these sectors have witnessed an acceleration in digital transformation. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. There is also huge potential for AI in medical diagnostics. However, using healthcare data for AI development raises data privacy concerns, thereby limiting its adoption.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close